Back to Blog

Patent Term Adjustment and Extension

April 26, 2026 Aruna 10 min read
patent term adjustment and extension of U.S. patent term

Patent term adjustment is the closest thing U.S. patent law has to compensation for lost time, and it is routinely miscalculated – sometimes by the Office, more often by applicants who trade away term without noticing. This guide covers the overlap rule after Wyeth, the terminal-disclaimer cap in 35 U.S.C. 154(b)(2)(B), and the hard limits on patent term extension under 35 U.S.C. 156.

The standard term of a U.S. utility patent is 20 years from the earliest effective filing date. However, two mechanisms can add time to this baseline term: patent term adjustment (PTA) and patent term extension (PTE). Understanding these mechanisms is essential for maximizing the commercial value of your patent portfolio, particularly in industries where patent term is a critical component of business strategy — such as pharmaceuticals and medical devices. PerspireIP helps clients calculate, preserve, and challenge patent term adjustments as part of comprehensive portfolio management.

What Is Patent Term Adjustment?

Patent term adjustment compensates patent applicants for delays in the USPTO’s examination process that are attributable to the USPTO itself. Under 35 U.S.C. 154(b), the USPTO must adjust the patent term if the agency fails to meet certain examination timeliness standards. PTA is intended to ensure that applicants do not lose effective patent protection simply because the USPTO takes too long to examine their applications.

The USPTO calculates and provides the PTA on the face of each issued patent. However, the USPTO’s calculation is not always correct, and applicants have the right to request reconsideration of PTA calculations — a right that PerspireIP routinely exercises on behalf of clients when we identify calculation errors.

How Patent Term Adjustment Is Calculated

PTA is calculated based on three categories of delay, commonly called A-delay, B-delay, and C-delay.

A-Delay: USPTO Examination Deadlines

A-delay adds one day for each day the USPTO fails to meet specific examination timeliness requirements, including failing to mail a first office action within 14 months of the application filing date, failing to respond to an office action response within 4 months, failing to act on an appeal within 4 months of the decision, or failing to issue the patent within 4 months of the notice of allowance payment.

B-Delay: Overall Pendency

B-delay adds one day for each day the application has been pending more than 3 years from the actual US filing date (not the priority date), with certain periods excluded such as time spent in an RCE, an appeal, or at the applicant’s request.

C-Delay: Interference, Secrecy Orders, and Appeals

C-delay compensates for delays caused by derivation proceedings, secrecy orders, or successful appeals. If you appeal an examiner’s rejection to the PTAB and the PTAB reverses the rejection, you receive credit for the time spent in the appeal process.

Applicant Delays That Reduce PTA

The PTA calculation also subtracts delays attributable to the applicant. Common applicant delays that reduce patent term adjustment include failing to respond to an office action within 3 months of the mailing date (even with extension fees paid), filing an RCE, filing a continuation application, submitting an Information Disclosure Statement (IDS) after a first office action that lists references that were available at the time of filing, and requesting extensions of time for responses.

Understanding how applicant behavior affects PTA is important for portfolio management. In patent families where long patent term is especially valuable, attorneys may advise responding to office actions as quickly as possible to minimize applicant-caused delays.

Challenging USPTO PTA Calculations

The USPTO’s PTA calculation is printed on the face of every issued patent. Applicants have two months from the date of patent grant to file a request for reconsideration of the PTA calculation if they believe it is incorrect. PerspireIP routinely reviews PTA calculations for clients upon patent issuance and files reconsideration requests when we identify errors. Common errors include incorrect calculation of A-delay periods, improper attribution of delays to the applicant rather than the USPTO, and mathematical calculation errors.

If the USPTO denies your reconsideration request, you may appeal the PTA determination to the United States District Court for the Eastern District of Virginia within 180 days of the denial. Several companies have successfully won additional patent term through such appeals, including cases that resulted in months of additional protection worth millions of dollars in pharmaceutical markets.

What Is Patent Term Extension?

Patent term extension is a separate mechanism from PTA that is specifically available to pharmaceutical products, medical devices, food additives, color additives, and animal drugs that required FDA regulatory review before commercial marketing. Under 35 U.S.C. 156, a patent covering one of these regulated products may be extended to compensate for time lost during the FDA regulatory review process.

PTE can add up to 5 years to the patent term, with the extended term not exceeding 14 years of remaining patent term after regulatory approval. For pharmaceutical patents, this can represent hundreds of millions of dollars in additional revenue from exclusive marketing rights.

How to Apply for Patent Term Extension

To obtain a patent term extension, you must file an application with the USPTO within 60 days of the FDA’s approval of the product. The application must identify the specific patent being extended, the regulatory review period, and the first permitted commercial marketing date. Only one patent per regulatory approval can be extended, and the patent must claim the active ingredient of the approved product (or a method of use or manufacture of the active ingredient). The USPTO and FDA jointly evaluate PTE applications, and the process can take 2-3 years.

Strategic Importance of Patent Term in Pharmaceuticals

For pharmaceutical companies, every additional day of patent term translates directly into revenue. A blockbuster drug generating $5 million per day in sales has $1.825 billion in annual value — making even a few months of additional patent term enormously important. Pharmaceutical patent portfolio management includes both optimizing PTA during prosecution (by minimizing applicant-caused delays) and securing PTE after FDA approval to maximize the exclusivity period.

How PerspireIP Helps Maximize Patent Term

PerspireIP provides comprehensive patent term adjustment and extension services. We calculate PTA during prosecution to advise on response timing, review USPTO PTA calculations upon issuance and file reconsideration requests where appropriate, and assist pharmaceutical and medical device clients with PTE applications following FDA approval. Our goal is to ensure that every day of patent protection you are entitled to is preserved.

Overlapping Delay and the Wyeth Correction

The single largest source of understated patent term adjustment was, for years, the way the Office handled overlap between A-delay and B-delay.

The statutory instruction is in 35 U.S.C. 154(b)(2)(A): to the extent that periods of delay attributable to the specified grounds overlap, the adjustment shall not exceed the actual number of days the issuance of the patent was delayed. The purpose is straightforward – the applicant should be compensated once for a day lost, not twice.

The USPTO read that provision to mean that where an application incurred both A-delay and B-delay, the applicant received the greater of the two rather than the sum. In Wyeth v. Kappos the Federal Circuit rejected that reading. Periods overlap only when they occur on the same calendar day. Because A-delay is measured against specific examination milestones and B-delay only begins to accrue three years after the actual U.S. filing date, the two often cover entirely different stretches of the prosecution – and where they do, they are added, not merged.

The practical significance survives the case. The Office corrected its calculation methodology, but the underlying arithmetic is still error-prone, particularly in families with RCEs, appeals and multiple continuations where the exclusion periods are complex. A PTA figure printed on the front page of a patent is a computation, not a finding, and computations can be wrong in either direction.

Two routes exist to fix an error. A request for reconsideration goes to the Office within two months of grant. Beyond that, 35 U.S.C. 154(b)(4)(A) provides an exclusive judicial remedy: a civil action in the United States District Court for the Eastern District of Virginia, filed within 180 days of the Director’s decision on the request for reconsideration. Both windows are short relative to how long it takes anyone to notice, which is the practical argument for reviewing PTA at issuance rather than when the patent becomes commercially interesting.

How a Terminal Disclaimer Can Erase Your Patent Term Adjustment

This is the trap that costs applicants the most term, and it is almost always self-inflicted during prosecution by someone focused on getting to allowance.

35 U.S.C. 154(b)(2)(B) is unambiguous: no patent the term of which has been disclaimed beyond a specified date may be adjusted under this section beyond the expiration date specified in the disclaimer. Filing a terminal disclaimer to overcome an obviousness-type double patenting rejection therefore does more than tie two patents together. It caps the later patent at the earlier one’s expiry date and any patent term adjustment above that cap simply disappears.

The asymmetry matters. A continuation that took years to prosecute may have accrued substantial adjustment precisely because it was slow. If that continuation is then terminally disclaimed over a parent that issued quickly and carries little or no adjustment, the accrued term is written off in a single filing.

  • Calculate the adjustment the application has accrued before filing a terminal disclaimer, not after.
  • Test whether the double patenting rejection can be overcome on the merits – by claim amendment or by argument on the differences – before conceding term.
  • Consider which family member should carry the commercially important claims, since the disclaimer binds the disclaiming patent to the reference patent’s date.
  • Where several continuations are pending, the sequencing of allowances can determine how much term the family retains in total.

None of this argues against terminal disclaimers as such. They are often the correct, proportionate response to a well-founded rejection, and the alternative – a protracted argument that delays grant – has its own cost. The point is that the trade should be priced. A terminal disclaimer filed reflexively at the end of prosecution is a decision to surrender term made by whoever happened to be preparing the response.

The Limits of Patent Term Extension Under Section 156

Patent term extension is a different animal from patent term adjustment. Adjustment compensates for Office delay; extension compensates for the regulatory review period a product spends waiting for marketing approval. Both can apply to the same patent, but section 156 comes with hard ceilings that shape portfolio strategy long before approval.

Four constraints do most of the work.

  1. A five-year cap. The extension may not exceed five years from the expiration of the original patent term.
  2. A fourteen-year post-approval cap. Where the term remaining after approval already exceeds fourteen years, the extension is reduced so that the total of the remaining term and the extension does not exceed fourteen years.
  3. One patent per product. No more than one patent may be extended for the same regulatory review period for any product. A portfolio with a compound patent, a formulation patent and a method-of-treatment patent must choose.
  4. A sixty-day filing window. The application for extension may only be submitted within the sixty-day period beginning on the date the product receives permission for commercial marketing or use.

The sixty-day window is the one that ends careers. It runs from approval, not from notification, and it is not a deadline that can be extended for good cause. The internal handoff between the regulatory team that receives approval and the patent team that must file within two months is the highest-risk moment in the whole process, and it should be rehearsed before it happens rather than managed when it does.

The one-patent-per-product rule deserves analysis well ahead of approval. Choosing which patent to extend means comparing the scope each one actually gives against how long each would run once extended – a broad compound claim expiring early may or may not beat a narrower formulation claim expiring later, and the answer depends on what competitors are likely to design around. That analysis takes time and data. Sixty days is not when to start it.

Conclusion

Patent term adjustment and patent term extension are powerful mechanisms for maximizing the commercial value of your patents. Understanding how PTA is calculated, how to minimize applicant delays, and when to challenge USPTO calculations is essential for any serious patent portfolio strategy. PerspireIP has the expertise to help you capture every day of patent term you are entitled to. Contact us today to review your portfolio for PTA and PTE opportunities.